Industry Analysis

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Restenosis Pipeline Review, H2 2017” to its report offerings. The report covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297808

Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restenosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Restenosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Restenosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively. Restenosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Restenosis (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Restenosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Restenosis (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Restenosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Restenosis (Cardiovascular) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Restenosis (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Restenosis (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/restenosis-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Restenosis - Overview Restenosis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Restenosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297808

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Raynauds Disease Pipeline Review, H2 2017” to its report offerings. The report reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297810

Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively. Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Raynauds Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Raynauds Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease (Cardiovascular) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Raynauds Disease (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Raynauds Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/raynauds-disease-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Raynauds Disease - Overview Raynauds Disease - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Raynauds Disease - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297810

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Pulmonary Embolism Pipeline Review, H2 2017” to its report offerings. The report reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297809

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/pulmonary-embolism-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pulmonary Embolism - Overview Pulmonary Embolism - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Pulmonary Embolism - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297809

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2017” to its report offerings. The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297804

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The report 'Prostaglandin E2 Receptor EP4 Subtype Pipeline Review, H2 2017' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis. Scope - The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects - The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/prostaglandin-e2-receptor-ep4-subtype-prostanoid-ep4-receptor-or-ptger4-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Overview 6 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 12 Products under Development by Universities/Institutes 16 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297804

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Pipeline Review, H2 2017” to its report offerings. The report  is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297803

Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Prostaglandin D2 (PGD2) receptors are G protein-coupled receptors that binds and is activated by prostaglandin D2. It mediates the pro-inflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 3 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology and Ophthalmology which include indications Asthma, Atopic Dermatitis, Allergic Asthma, Allergic Rhino-Conjunctivitis, Androgenic Alopecia, Allergic Rhinitis, Allergies, Chronic Obstructive Pulmonary Disease (COPD) and Inflammation. The latest report Prostaglandin D2 Receptor 2 Pipeline Review, H2 2017, outlays comprehensive information on the Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - The report reviews Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/prostaglandin-d2-receptor-2-chemoattractant-receptor-homologous-molecule-expressed-on-th2-cells-or-g-protein-coupled-receptor-44-or-gpr44-or-cd294-or-ptgdr2-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Overview 7 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Prostaglandin D2 Receptor 2 (Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2) Therapeutics Assessment 14 Assessment by Mechanism of Action 14 Assessment by Route of Administration 15 Assessment by Molecule Type 16

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297803

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017” to its report offerings. The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297807

According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke. Scope - The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects - The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/metabotropic-glutamate-receptor-2-gprc1b-or-mglur2-or-grm2-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Overview 7 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297807

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017” to its report offerings. The report  is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party source.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297806

Glucagon Like Peptide 2 Receptor (GLP2R) Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition. Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology which include indications Short Bowel Syndrome, Chemotherapy Effects, Diabetes, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes. The latest report Glucagon Like Peptide 2 Receptor (GLP2R) Pipeline Review, H2 2017, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R) - The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects - The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/glucagon-like-peptide-2-receptor-glp2r-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glucagon Like Peptide 2 Receptor (GLP2R) Overview 6 Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 10 Glucagon Like Peptide 2 Receptor (GLP2R) Therapeutics Assessment 12 Assessment by Mechanism of Action 12 Assessment by Route of Administration 13 Assessment by Molecule Type 15 Glucagon Like Peptide 2 Receptor (GLP2R) Companies Involved in Therapeutics Development 17 Hanmi Pharmaceuticals Co Ltd 17

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297806

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Epilepsy Pipeline Review, H2 2017” to its report offerings. The report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297813

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 13, 21, 2, 85, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively. Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/epilepsy-pipeline-review-h2-2017-report.html

Table of Contents:

Introduction 6 Epilepsy - Overview 7 Epilepsy - Therapeutics Development 8 Epilepsy - Therapeutics Assessment 31 Epilepsy - Companies Involved in Therapeutics Development 45 Epilepsy - Drug Profiles 81 Epilepsy - Dormant Projects 382 Epilepsy - Discontinued Products 389 Epilepsy - Product Development Milestones 391

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297813

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2” to its report offerings. The report overs products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297831

According to the recently published report 'C-X-C Chemokine Receptor Type 4 – Pipeline Review, H2 2017'; C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 26 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

The report 'C-X-C Chemokine Receptor Type 4 – Pipeline Review, H2 2017' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Immunodeficiency Virus (HIV) Infections (AIDS), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Asthma, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects - The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects -  The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/cxc-chemokine-receptor-type-4-report.html

Table of Contents:

Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Overview 9 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 16 Products under Development by Universities/Institutes 21

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297831

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H2 2017” to its report offerings. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297801

The C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Cardiovascular, Central Nervous System, Infectious Disease and Metabolic Disorders which include indications Inflammation, Metastatic Breast Cancer, Asthma, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Pain, Liver Transplant Rejection, Lung Infections, Lung Transplant Rejection, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Post-Operative Pain, Prostate Cancer, Pulmonary Inflammation, Respiratory Syncytial Virus (RSV) Infections, Solid Tumor, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections. The latest report C-X-C Chemokine Receptor Type 2 Pipeline Review, H2 2017, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - The report reviews C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics and enlists all their major and minor projects - The report assesses C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/c-x-c-chemokine-receptor-type-2-cdw128b-or-gromgsa-receptor-or-high-affinity-interleukin-8-receptor-b-or-il8-receptor-type-2-or-cd182-or-cxcr2-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) Overview 7 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297801

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Encephalomyelitis Pipeline Review, H2 2017” to its report offerings. The report reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297811

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively. Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/encephalomyelitis-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Encephalomyelitis - Overview Encephalomyelitis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Encephalomyelitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297811

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017” to its report offerings. The report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297815

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 1 and 1 respectively. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Overview Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Therapeutics Assessment Assessment by Target Assessment by Route of Administration Assessment by Molecule Type

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297815

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2017” to its report offerings. The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297800

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 5 Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Infectious Disease, Gastrointestinal, Immunology, Oncology, Genito Urinary System And Sex Hormones, Metabolic Disorders and Musculoskeletal Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Non-Alcoholic Steatohepatitis (NASH), Graft Versus Host Disease (GVHD), Autoimmune Disorders, Diabetic Nephropathy, Fibrosis, Kidney Fibrosis, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non Alcoholic Fatty Liver Disease (NAFLD), Peritonitis, Pre-Diabetes/Impaired Glucose Tolerance, Primary Sclerosing Cholangitis and Type 2 Diabetes. Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects - The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/c-c-chemokine-receptor-type-5-chemr13-or-hiv-1-fusion-coreceptor-or-cd195-or-ccr5-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Overview 7 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 11 Products under Development by Universities/Institutes 14 C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Therapeutics Assessment 16 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297800

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Dementia Pipeline Review, H2 2017” to its report offerings. The report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297812

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively. Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/dementia-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 Introduction 5 Dementia - Overview 6 Dementia - Therapeutics Development 7 Dementia - Therapeutics Assessment 20 Dementia - Companies Involved in Therapeutics Development 31 Dementia - Drug Profiles 57 Dementia - Dormant Projects 216 Dementia - Discontinued Products 220 Dementia - Product Development Milestones 221

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297812

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2017” to its report offerings. The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297802

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Pipeline Review, H2 2017, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis. Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects - The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read Full Report with TOC: http://www.marketresearchhub.com/report/c5a-anaphylatoxin-chemotactic-receptor-1-cd88-or-c5ar1-pipeline-review-h2-2017-report.html

Table of Contents:

Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Overview 6 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Development 7 Products under Development by Stage of Development 7 Products under Development by Therapy Area 8 Products under Development by Indication 9 Products under Development by Companies 11 Products under Development by Universities/Institutes 13 C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) Therapeutics Assessment 15 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 18

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297802

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 18, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Batten Disease Pipeline Review, H2 2017” to its report offerings. The report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1297814

Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone and movement problems. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Batten Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Batten Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Batten Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Batten Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively. Batten Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Batten Disease (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Batten Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Batten Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Batten Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Batten Disease (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Batten Disease (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Batten Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Read Full Report with TOC: http://www.marketresearchhub.com/report/batten-disease-pipeline-review-h2-2017-report.html

Table of Contents:

List of Tables List of Figures Introduction Global Markets Direct Report Coverage Batten Disease - Overview Batten Disease - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Batten Disease - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1297814

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Albany, New York, August 17, 2017: Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Phenylketonuria Market Insights, Epidemiology and Market Forecast-2025” to its report offerings. The report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Phenylketonuria (PKU).

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265871

The report provides an overview of the disease and in depth research related to Phenylketonuria (PKU) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Phenylketonuria (PKU) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Phenylketonuria (PKU) for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Phenylketonuria (PKU) market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Phenylketonuria (PKU) , providing an in-depth analysis of emerging therapies which will create an impact through their launch. According to DelveInsight, the forecasted patient population of Phenylketonuria (PKU) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Phenylketonuria (PKU) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Phenylketonuria (PKU) market from inside out, with transparency into the calculated patient forecasting data and estimated market size. Key Coverage Understanding historical and forecasted epidemiological data for Phenylketonuria (PKU) covering 7MM from 2015-2025. Segment level epidemiology and market split for Phenylketonuria (PKU) . The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Phenylketonuria (PKU) . The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Phenylketonuria (PKU) market trends. Thorough market distribution based on market share for Phenylketonuria (PKU) . Reasons to buy The report will help in developing business strategies by understanding trends shaping and driving the Phenylketonuria (PKU) market. To understand the future market competition in the Phenylketonuria (PKU) market and Insightful review of the key market drivers and barriers. Organize sales and marketing efforts by identifying the best opportunities for Phenylketonuria (PKU) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Read Full Report with TOC: http://www.marketresearchhub.com/report/phenylketonuria-pku-market-insights-epidemiology-and-market-forecast-2025-report.html

Table of Contents:

Report Introduction 2. Phenylketonuria (PKU) Market Overview at a Glance 2.1. Total Market Share Distribution of Phenylketonuria (PKU) for 7 MM in 2016 2.2. Total Market Share Distribution of Phenylketonuria (PKU) for 7 MM in 2025 3. Phenylketonuria (PKU) 3.1.1. Overview 3.1.2. Symptoms 3.1.3. Pathophysiology 3.1.4. Staging 3.1.5. Diagnosis 3.1.6. Treatment 4. Epidemiology and Patient Population 4.1.1. United States 4.1.1.1. Diagnosed Cases of Phenylketonuria (PKU) in United States 4.1.2. Germany 4.1.2.1. Diagnosed Cases of Phenylketonuria (PKU) in Germany 4.1.3. France 4.1.3.1. Diagnosed Cases of Phenylketonuria (PKU) in France 4.1.4. Italy 4.1.4.1. Diagnosed Cases of Phenylketonuria (PKU) in Italy 4.1.5. Spain 4.1.5.1. Diagnosed Cases of Phenylketonuria (PKU) in Spain 4.1.6. United Kingdom 4.1.6.1. Diagnosed Cases of Phenylketonuria (PKU) in United Kingdom 5. Treatment Algorithm 5.1.1. Treatment Guidelines/Practices 6. Marketed Drugs for Phenylketonuria (PKU)

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1265871

About Market Research Hub:        

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 1-800-998-4852 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/